Magnolia Medical Technologies announced today a collaboration with Cardinal Health focused on improving clinical and economic outcomes by reducing blood culture contamination and false-positive diagnostic results for sepsis.
Through this collaboration, Cardinal Health will offer the Steripath® Gen2 Initial Specimen Diversion Device® (ISDD®) to hospitals as a standalone product, and as part of customizable Best Practices Kits to address the long-standing problem of blood culture contamination and its downstream impact on patient safety, quality outcome measures and healthcare costs.
“Continued increasing awareness of the patient safety and economic impacts of blood culture contamination has accelerated the demand and adoption of Steripath in hospitals nationwide,”said Greg Bullington, CEO of Magnolia Medical.
“We are thrilled to formalize our relationship with Cardinal Health to expand our distribution network and provide just-in-time logistics to meet this growing demand. This relationship significantly increases our sales and marketing reach and will drive further penetration of Steripath as a new standard of care for sepsis testing accuracy. The collective commitment of both of our organizations to improve patient safety, help hospitals achieve their formal quality measure goals, all while significantly reducing unnecessary hospital costs, serves as a strong foundation for the success of this partnership,” said Bullington.
Each year, tens of millions of patients in the U.S. require a blood culture test for diagnosis of sepsis and other bloodstream infections. On average, 3 percent of these tests are false positive due to contamination. These false-positive results place over 1.2 million patients at risk of a misdiagnosis for sepsis. These patients are often treated with unnecessary antibiotics and spend, on average, two additional days in the hospital, increasing their risk of antibiotic-resistant infections, C. difficile and other antibiotic-related complications.
The Steripath Gen2 ISDD diverts and isolates the initial 1.5 to 2.0 mL of blood, the portion known to most likely contain contaminants, demonstrating up to 92 percent reduction in blood culture contamination, with sustained rates as low as 0.2 percent in the Emergency Department. It is the only technology of its kind backed by 14 clinical studies, including five publications in leading peer-reviewed medical journals.
Steripath Gen2 stand-alone products, and the Steripath Best Practice Kits are both supported by a Magnolia money-back clinical performance guarantee of a minimum 50 percent sustained reduction in blood culture contamination. Best Practice Kits are further supported by a 0.5 percent contamination rate guarantee, giving customers confidence in achieving their patient care and cost saving goals.
“We are pleased Cardinal Health is integrating the Steripath product portfolio into their product offerings. The unique combination of the Steripath Gen2 ISDD clinical evidence, device performance guarantee and Cardinal Health’s market presence will help drive further adoption of a new standard of care enabling sepsis testing accuracy and improving patient safety,” said Bob Gerberich, CCO of Magnolia Medical.